Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
NCT04535960 on ClinicalTrials.gov · last registry update 2023-05-17
A small phase 2 — 36 participants, against a typical 110. Its estimated completion date, October 2023, has passed with no update to the record. Primary outcome, as filed: Proximal tubular natriuresis. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor type
- Other
- Enrollment
- 36
- Started
- 2019-01-24
- Primary completion
- 2023-10 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proximal tubular natriuresis
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.